The Long-term Prognosis of Moderate to Severe Bronchial Hyperresponsiveness (BHR) in Asthmatic Preschool Children

Conditions:   Intrinsic Asthma;   Allergic Asthma;   Allergy;   Bronchial Hyperresponsiveness
Interventions:   Other: methacholine bronchial challenge;   Other: methacholine bronchial challenge
Sponsor:   Johann Wolfgang Goethe University Hospitals
Not yet recruiting – verified September 2010

View full post on ClinicalTrials.gov: “Asthma” | updated in the last 30 days

A Randomised, Double- Blind, Placebo Controlled, Cross-over Efficacy and Safety Comparison of Tiotropium 5 µg Once Daily and Tiotropium 2.5 µg Twice Daily for Four Weeks in Patients With Moderate Persistent Asthma

Condition:   Asthma
Interventions:   Drug: Placebo;   Drug: Tiotropium 5 µg q.d.;   Drug: Tiotropium 2.5 µg b.i.d.
Sponsors:   Boehringer Ingelheim Pharmaceuticals;   Pfizer
Recruiting – verified September 2010

View full post on ClinicalTrials.gov: “Asthma” | updated in the last 30 days

Evaluation of Tiotropium 2.5 and 5 Mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 Mcg Twice Daily) in Patient With Moderate Persistent Asthma II

Condition:   Asthma
Interventions:   Drug: 50 mcg salmeterol HFA MDI;   Drug: placebo;   Drug: 5 mcg tiotropium Respimat®;   Drug: 2.5 mcg tiotropium Respimat®
Sponsors:   Boehringer Ingelheim Pharmaceuticals;   Pfizer
Recruiting – verified September 2010

View full post on ClinicalTrials.gov: “Asthma” | updated in the last 30 days